efgartigimod (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

Myasthenia Gravis

Pending FDA approval for myasthenia gravis

Next:

Pharmacology

Mechanism of Action

Antibody fragment that targets the neonatal Fc receptor (FcRn), thereby reducing IgG antibodies

FcRn bind IgGs and rescues them from lysosomal degradation, extending IgG half-life (~21 days) compared with IgM or IgA (~5 days), not recycled by FcRn3-5; prolonged half-life of pathogenic IgGs increases their ability to impair neuromuscular transmission

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.